The obesity drug market is projected to reach $173.5 billion by 2031, with increasing awareness and new drug developments despite current affordability challenges.

‘Did you know?
More than 200 million people are living with #obesity in the US, France, Germany, Italy, Spain, UK, and Japan. #7MM #obesitydrugs #medindia ’

More than 200 million people are living with #obesity in the US, France, Germany, Italy, Spain, UK, and Japan. #7MM #obesitydrugs #medindia ’





Obesity Drug Market to Hit $173.5 Billion in Sales
With physicians' and patients' awareness expected to increase, sales of obesity medications are estimated to reach $173.5 billion in the seven major markets (7MM - US, France, Germany, Italy, Spain, the UK, and Japan).The GlobalData report also reveals that the revolution in obesity treatments is still in progress and many changes are required to meet the needs in obesity therapeutics. Costanza Alciati, Pharma Analyst at GlobalData comments that therapies for obesity are still limited and many patients cannot access them as they are not affordable.
The most effective weight loss drugs on the market are Eli Lilly’s Mounjaro/Zepbound (tirzepatide) and Novo Nordisk’s Wegovy (semaglutide), which are expected to continue generating high sales for their respective manufacturers.
New Obesity Drugs in Development
More than 200 million people are living with obesity in 7MM, and it will increase at an annual growth rate (AGR) of 0.7% until 2031. Although Eli Lily and Novo Nordisk can maintain their market for obesity drugs, the development of new drugs has a big opportunity.Pipeline therapies in development include drugs with new mechanisms of action, longer action resulting in a reduced number of treatment days, and oral candidates as potent as currently available injectables.
Advertisement
Advertisement